英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
337909查看　337909　在百度字典中的解释百度英翻中〔查看〕
337909查看　337909　在Google字典中的解释Google英翻中〔查看〕
337909查看　337909　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Davunetide in patients with progressive supranuclear palsy: a . . .
    313 participants were randomly assigned to davunetide (n=157) or to placebo (n=156), and 241 (77%) completed the study (118 and 156 in the davunetide and placebo groups, respectively) There were no differences in the davunetide and placebo groups in the baseline PSPRS and SEADL
  • Davunetide in patients with progressive supranuclear palsy: a . . .
    Findings 313 participants were randomly assigned to davunetide (n=157) or to placebo (n=156), and 241 (77%) completed the study (118 and 156 in the davunetide and placebo groups, respectively) There were no differences in the davunetide and placebo groups in the baseline PSPRS and SEADL
  • Davunetide in patients with progressive supranuclear palsy: a . . .
    Findings 313 participants were randomly assigned to davunetide (n=157) or to placebo (n=156), and 241 (77%) completed the study (118 and 156 in the davunetide and placebo groups, respectively) There were no differences in the davunetide and placebo groups in the baseline PSPRS and SEADL
  • Davunetide in patients with progressive supranuclear palsy: a . . .
    There were no differences in the davunetide and placebo groups in the baseline PSPRS and SEADL
  • Davunetide in patients with progressive supranuclear palsy: a . . .
    Because progressive supranuclear palsy (PSP) is linked to tau pathology, davunetide could be a treatment for PSP We assessed the safety and effi cacy of davunetide in patients with PSP
  • 進行性核上性麻痺患者におけるダブネチド: 無作為化二重盲検 . . .
    前臨床研究において,ダブネチドは微小管安定性を促進し,タウリン酸化を減少させた。 進行性核上性麻痺 (PSP)はタウ病理学と関連するので,ダブネチドはPSPの治療である。 PSP患者におけるダブネチドの安全性と有効性を評価した。 二重盲検,平行群,相2 3試験において,参加者は,オーストラリア,カナダ,フランス,ドイツ,英国,および米国の48センターで,ダブネチド (30mgの1日2回,鼻腔内)またはプラセボに対する1:1の比率で,無作為に,1対1の割合で,1つの比率において,パーミューテーションされたブロックで割り当てられた。 参加者は,PSPに対するParkinson Plus症候群研究基準における修正神経保護と自然史を満たした。
  • Davunetide in patients with progressive supranuclear palsy: a . . .
    Because progressive supranuclear palsy (PSP) is linked to tau pathology, davunetide could be a treatment for PSP We assessed the safety and efficacy of davunetide in patients with PSP
  • Davunetide in patients with progressive supranuclear palsy: A . . .
    Findings: 313 participants were randomly assigned to davunetide (n=157) or to placebo (n=156), and 241 (77%) completed the study (118 and 156 in the davunetide and placebo groups, respectively) There were no differences in the davunetide and placebo groups in the baseline PSPRS and SEADL
  • Unexpected gender differences in progressive supranuclear . . .
    Progressive supranuclear palsy (PSP) is a pure tauopathy, implicating davunetide, enhancing Tau-microtubule interaction, as an ideal drug candidate However, pooling patient data
  • Davunetide Fails to Show Efficacy in Progressive . . .
    A large-scale Phase 2 3 clinical trial of the investigational drug davunetide in patients with progressive supranuclear palsy (PSP) did not meet its primary efficacy endpoints, showing no significant difference from placebo in slowing disease progression
  • davunetide progressive supranuclear palsy trial results
    Overall Conclusion: The trial conclusively showed that davunetide was not effective in slowing disease progression in PSP over 52 weeks, despite being well-tolerated [1] [2] [3]





中文字典-英文字典  2005-2009